Stay updated on Nivolumab Plus Ipilimumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-10T12:17:23.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden message, replacing the previous study record content. The header shows minimal navigation and a footer with revision information, indicating a restricted or error state.
    Difference
    17%
    Check dated 2026-09-19T19:15:16.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    Removed related topics entries for Melanoma and MedlinePlus Genetics from the page. This changes the available topic links without altering the primary study details.
    Difference
    0.1%
    Check dated 2026-09-05T19:18:17.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The page now includes NIH grant attribution and 'Melanoma' as a topic, adds a related topics link to MedlinePlus Genetics, and updates the revision from v3.6.5 to v3.6.6.
    Difference
    0.1%
    Check dated 2026-08-29T18:47:54.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    The page no longer lists Melanoma as a condition and removes related topics/MedlinePlus Genetics links. This reduces the disease context and associated educational resources on the study record.
    Difference
    0.1%
    Check dated 2026-08-22T16:58:19.000Z thumbnail image
  8. Check
    57 days ago
    Change Detected
    Summary
    The page now includes Melanoma under related topics and a MedlinePlus Genetics entry in the related topics area. These additions provide quick access to disease context and genetics resources from the study page.
    Difference
    0.1%
    Check dated 2026-08-15T13:45:33.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Melanoma Clinical Trial page.